SUPN — Supernus Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.30bn
- $1.93bn
- $718.95m
Brief: S&P Dow Jones Indices Msg Rangers And Huron Consulting Group Set To Join S&P Smallcap 600
Brief: Supernus Pharmaceuticals Says FDA Grants Seven Years Orphan-Drug Exclusivity For Onapgo
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE -Micron Technology, Ares Management, Boeing
U.S. STOCKS ON THE MOVE -Visa, Bowhead Specialty, Micron
U.S. STOCKS ON THE MOVE-CNH Industrial, Lantheus Holdings, Visa
Supernus soars on Indivior merger, Q2 revenue beat
Supernus, Indivior merge to strengthen neuroscience drug portfolio
Supernus Q2 revenue rises on prescription volume; to merge with Indivior Pharma
Supernus reiterates full-year 2026 financial guidance
Brief: Supernus Pharmaceuticals Q1 Product Sales USD 150.8 Million
Brief: Supernus Pharmaceuticals Inc Enters Asset Purchase Agreement With Navitor On April 1, 2026
Supernus Pharmaceuticals Q4 revenue rises 21% on product sales
Supernus Pharma Q3 revenue rises, partly helped by Sage acquisition
U.S. RESEARCH ROUNDUP-Carmax, Mirion Technologies, Valmont Industries
Brief: Biogen Receives European Commission Approval For Zurzuvae
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Supernus Pharmaceuticals Q2 Product Sales USD 158 Million
Brief: Supernus Pharmaceuticals Completes Acquisition Of Sage Therapeutics